An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)

This observational study will evaluate the effect on disease activity and the safety in routine clinical practice of MabThera (rituximab) in participants with active seropositive rheumatoid arthritis, who have an inadequate response to one or more tumour necrosis factor inhibitor (anti-TNF) therapies.

Inclusion Criteria:

• Age >18 years with rheumatoid arthritis (RA)
• Seropositive participants with RA (positive for rheumatoid factor (RF) and/or anti-Citrullinated Cyclic Peptide [CCP])
• Active disease despite receiving one or more TNF inhibitors
• Absence of serious or active infection

Exclusion Criteria:

• Participants with serious history of heart failure (class New York Heart Association [NYHA] IV) or severe uncontrolled heart disease
• Participants pregnant or lactating
• Prior treatment with Mabthera®
• Participants receiving any other investigational product in the context of other clinical study
• Participants with known hypersensitivity to rituximab or to any of the excipients